KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Goodwill & Intangibles: 2022-2024

Historic Goodwill & Intangibles for Rigel Pharmaceuticals (RIGL) over the last 3 years, with Dec 2024 value amounting to $27.1 million.

  • Rigel Pharmaceuticals' Goodwill & Intangibles fell 8.49% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.3 million, marking a year-over-year decrease of 8.49%. This contributed to the annual value of $27.1 million for FY2024, which is 95.27% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Goodwill & Intangibles stood at $27.1 million for FY2024, which was up 95.27% from $13.9 million recorded in FY2023.
  • Rigel Pharmaceuticals' Goodwill & Intangibles' 5-year high stood at $27.1 million during FY2024, with a 5-year trough of $13.9 million in FY2023.
  • Over the past 3 years, Rigel Pharmaceuticals' median Goodwill & Intangibles value was $14.9 million (recorded in 2022), while the average stood at $18.6 million.
  • In the last 5 years, Rigel Pharmaceuticals' Goodwill & Intangibles declined by 7.16% in 2023 and then soared by 95.27% in 2024.
  • Over the past 3 years, Rigel Pharmaceuticals' Goodwill & Intangibles (Yearly) stood at $14.9 million in 2022, then fell by 7.16% to $13.9 million in 2023, then surged by 95.27% to $27.1 million in 2024.